Herantis Pharma, Pelago Bioscience and Targovax are the recipients of the Nordic Stars Award 2017. The award was presented at the conclusion of the Nordic Life Science Days (NLSDays) in Malmö, which again set a new record for attendance. Over 1 300 delegates representing more than 800 companies from 40 countries joined the conference, thus confirming NLSDays’ role as the premier Nordic life sciences event.
Nordic Stars Award was introduced in 2013 in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.
Björn Ursing, Chairman of the Nordic Stars Award:
– At SwedenBIO we are proud to present the three winners of the Nordic Stars Award 2017. Each of them has demonstrated impressive entrepreneurial spirit, combined with a passion for developing innovative solutions for their respective clients or patient groups. Together, they are all excellent examples of how Nordic companies can contribute to better healthcare globally.
This year’s winners are:
Herantis Pharma, Finland
Herantis pharma follows a truly patient centric approach, addressing major unmet medical needs with a broad product portfolio in various therapeutic areas. They have several projects in clinical phase already showing promising results. Their basis in academia has also paved the way for extensive scientific collaborations.
Pelago Bioscience, Sweden
Pelago Bioscience provides a unique model for in situ target engagement studies. The company shows that a well-run service provider with a breakthrough technology can play a key role in developing more efficient processes for both preclinical and clinical drug development. With its partners, it shows true collaborative spirit.
Targovax has two clinical-stage immune-oncology projects with different approaches for solid tumors. Recently having secured a large private placement, Targovax now has the resources required to run the therapies in both stand-alone and combination trials.
Jonas Ekstrand, Director General of SwedenBIO also reflected on the highly successful two days.
– With more delegates and professional exchanges than ever in our five-year history in such a nice and pleasant atmosphere, Nordic Life Science Days has once again proved to be the premium conference, partnering and networking event within life science in Northern Europe. Join us next year again when the conference returns to Stockholm.
Nordic Life Science Days 2017 in brief
Registered Delegates: 1300+
Registered Companies: 800+
Countries Represented: 40
Partnering Meeting Requests: 16000+
Partnering Meetings Scheduled: 3000+
Back to Stockholm next year
Join us next year when Nordic Life Science Days 2018 are held in Stockholm on September 10-12.
NLSDays is a SwedenBIO event, produced by Bionordic. NLSDays was founded in 2012 and has grown rapidly to become the largest Nordic partnering conference for the global life science industry.
Among the investors and big pharma registered for the meeting include AbbVie, A. Menarini, Almi Invest, Amgen, AstraZeneca, Bayer, Bill & Melinda Gates Foundation, Boehringer Ingelheim, Bracknor Investment Group, Bristol-Myers Squibb, Cadila, CDC Investment Group, Daiichi Sankyo, Desitin ArzneimittelEA Pharma, Eli Lilly, Ferring Pharmaceuticals, Fouriertransform, Gilde Healthcare Partners, HealthCap, Huons, Hyundai Pharmaceuticals, Industrifonden, Johnson & Johnson, JT Pharma, Kyorin Pharmaceuticals, Medac, Mitsubishi Pharma, Monitus Research, MSD, Neomed, Novo Nordisk, Oberland Capital, Pathena VC, Pfizer, P.U.L.S., RBV Capital, Recordati, Reig Jofre, Roche, Saminvest, Sampoong Finechem, Sanofi, Sarsia Seed Fund, Servier, Seventure Partner, Sunstone, Taisho, Takeda, Thermo Fisher Scientific och UCB.
In addition to partnering, NLSDays also offers an exhibition and a seminar program. Speakers include senior representatives from the global life science companies, investors, and academic leaders who will all share their expertise and views for the future.
Läs mer på MyNewsDesk